TSHA - NASDAQ

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHAยทNASDAQ

$5.79

+1.7%
HealthcareBiotechnology

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.45B
EPS-0.3400
P/E Ratio-17.01
Earnings Date08/11/2026
Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. Fair Value Envelope

TSHA ยท NASDAQ

Our analysis suggests that TSHA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.785, this represents a potential HIDDEN relative to our calculated worth for Taysha Gene Therapies, Inc..

HIDDEN
Intrinsic Value
Current Price: $5.785

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$313.3M
+ Cash & Equivalents$319.8M
Firm Value$6.4M
- Debt$18.2M
Equity Value-$11.7M
/ Shares Outstanding300,476,190B
DCF Value-$0
OVERVALUED BY 101%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$79.1M
-$67.3M
-$57.2M
-$48.6M
-$41.3M
-$35.1M
-$29.9M
-$25.4M
-$21.6M
-$18.4M
Maintenance CapEx
-$125.5K
-$106.7K
-$90.7K
-$77.1K
-$65.5K
-$55.7K
-$47.4K
-$40.3K
-$34.2K
-$29.1K
Owner Earnings
-$79.3M
-$67.4M
-$57.3M
-$48.7M
-$41.4M
-$35.2M
-$29.9M
-$25.4M
-$21.6M
-$18.4M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$73.4M
-$57.8M
-$45.5M
-$35.8M
-$28.2M
-$22.2M
-$17.5M
-$13.7M
-$10.8M
-$8.5M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TSHA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.